
CureVac B.V (CVAC) Stock Forecast & Price Target
CureVac B.V (CVAC) Analyst Ratings
Bulls say
CureVac NV is strategically positioned within the competitive mRNA sector, leveraging the high value associated with COVID-19 vaccines to expand its portfolio into broader applications. The company demonstrates a strong pipeline with ongoing development programs, which include innovative mRNA vaccines for seasonal influenza, avian influenza, and oncology, indicating robust future revenue potential. As these initiatives progress according to plan, they enhance CureVac's long-term growth prospects and contribute positively to the company's overall financial outlook.
Bears say
CureVac is anticipated to continue incurring net losses at least until it achieves product approval and commercialization, which may extend into the early launch phase. The company faces significant competitive risks against both established products and in-development candidates, which could hinder its market position and future sales potential. Additionally, potential legal and intellectual property risks may further complicate its ability to capitalize on its pipeline, contributing to a challenging financial outlook.
This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.
CureVac B.V (CVAC) Analyst Forecast & Price Prediction
Start investing in CureVac B.V (CVAC)
Order type
Buy in
Order amount
Est. shares
0 shares